Agam R. Sheth
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Agam R. Sheth.
Journal of Physical Chemistry B | 2009
Xin S. Zhao; J. Ilja Siepmann; Wei Xu; Y.-H. Kiang; Agam R. Sheth; S. Karaborni
The pharmaceutical compound A, 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)propyl]imidazolidin-1-yl}-3(S)-(6-methoxypyridin-3-yl)propionic acid, is known to exist in five different crystalline forms that differ in the hydration state ranging from the anhydrous desolvate over hemihydrate, dihydrate, and tetrahydrate forms to the pentahydrate. The formation of the higher hydrates and the concomitant lattice expansion leads to undesirable tablet cracking at higher humidities. In this work, particle-based simulation techniques are used to explore the hydrate formation of compound A as a function of humidity. It is found that a simulation strategy employing Monte Carlo simulations in the isobaric-isothermal and Gibbs ensembles and transferable force fields, which are not parametrized against any experimental data for compound A, is able to yield satisfactory crystal structures for the anhydrate and pentahydrate and to predict the existence of all five hydrates.
Journal of Pharmaceutical Sciences | 2010
Christopher J. Mortko; Agam R. Sheth; Narayan Variankaval; Li Li; Brian T. Farrer
(1S,5R)-2-{[(4S)-azepan-4-ylamino]carbonyl}-7-oxo-2,6-diazabicyclo[3.2.0] heptane-6-sulfonic acid (Compound 1) is a β-lactamase inhibitor for intravenous administration. The objective of this preformulation study was to determine the most appropriate form of the API for development. Compound 1 can exist as an amorphous solid and four distinct crystalline phases A, B, C, and D in the solid state. Slurry experiments along with analysis of physicochemical properties were used to construct a phase diagram and select the most suitable form of the API for development. In aqueous formulations, the dihydrate form of the API was predominant and, due to the more favorable solubility and dissolution profile required for preclinical and clinical studies, a metastable form of the API was selected, and the risks associated with developing this form were evaluated.
Journal of the American Chemical Society | 2005
Agam R. Sheth; Joseph W. Lubach; Eric J. Munson; Francis X. Muller; David J. W. Grant
Crystal Growth & Design | 2004
Agam R. Sheth; Simon Bates; Francis X. Muller; David J. W. Grant
Crystal Growth & Design | 2005
Agam R. Sheth; Simon Bates; Francis X. Muller; David J. W. Grant
Archive | 2006
Agam R. Sheth; Bhagwant Rege; Soumojeet Ghosh; Laman Alani; Craig McKelvey; Maria T. Cruanes
Crystal Growth & Design | 2006
Collin D. Wick; J. Ilja Siepmann; Agam R. Sheth; David J.W. Grant; Sami Karaborni
Archive | 2017
Agam R. Sheth; Pavithra Sundararajan; Elise Miller; Justin Moser; Adam Socia; Angela M. Wagner
Archive | 2016
Pavithra Sundararajan; Agam R. Sheth; Jesse Kuiper; Patrick J. Marsac; Elise Miller; Justin Moser; Adam Socia; Angela M. Wagner
Archive | 2006
Agam R. Sheth; Bhagwant Rege; Soumojeet Ghosh; Laman Alani; Craig McKelvey; Maria T. Cruanes